CCNG2 and breast carcinoma: A recent study by Li et al. indicated that miR-1246 enhances CyclinG2-mediated proliferation, migration and chemoresistance to DOX, Epi and gemcitabine by targeting the expression of Cyclin G2 in breast cancer [456].